Researchers define two categories of multiple sclerosis patients

There are approximately 400,000 people in the United States with multiple sclerosis. Worldwide, the number jumps to more than 2.1 million people. Rather than a one-size-fits-all approach to treating the millions with multiple sclerosis, what if doctors could categorize patients to create more personalized treatments? A new study by researchers at Brigham and Women's Hospital (BWH) may one day make this idea a reality in the fight against the debilitating autoimmune disease.

A research team led by Philip De Jager, MD, PhD, BWH Department of Neurology, senior study author, has found a way to distinguish patients with into two meaningful subsets. The ability to categorize patients with multiple sclerosis may open new doors for treatment development.

The study will be electronically published on September 26, 2012 in Science Translational Medicine.

"Our results suggest that we can divide the multiple sclerosis patient population into groups that have different levels of disease activity," said De Jager. "These results motivate us to improve these distinctions with further research so that we may reach our goal of identifying the best treatment for each individual who has multiple sclerosis."

De Jager and his team extracted RNA—key molecules involved in making proteins from the instructions found in the DNA sequence—from of patients with multiple sclerosis. After analyzing the samples, they found distinct sets of among the patient samples. These unique sets formed a transcriptional signature that distinguished two sets of multiple sclerosis patients—MSa patients and MSb —with those in the MSa group having a higher risk for future multiple sclerosis relapse.

According to the researchers, knowing the category a person with multiple sclerosis is in may help doctors make more informed . For instance, since a patient who falls into the MSa category is more likely to experience relapse, her doctor may consider a stronger treatment for the patient.

In light of the discovery, the researchers remain cautious about the findings.

"Our study is an important step towards the goal of personalized medicine in MS, but much work remains to be done to understand under which circumstance and in combination with which other information this transcriptional signature may become useful in a clinical setting," said De Jager.

However, from the pre-clinical perspective, the researchers recognize that the findings are essential because they build on earlier studies that had suggested that this structure might be present.

"The study will further enable the community of MS researchers to build upon this transcriptional signature with other data in order to enhance patient care in the future," said De Jager.

Related Stories

Young smokers increase risk for multiple sclerosis

Feb 23, 2009

People who start smoking before age 17 may increase their risk for developing multiple sclerosis (MS), according to a study released today that will be presented at the American Academy of Neurology's 61st Annual Meeting ...

Recommended for you

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

Mike_Massen
5 / 5 (1) Sep 26, 2012
From what I have read and seen on recent documentaries in Australia, the bacteria http://en.wikiped...eumoniae
and its toxins have been found in the brain of MS patients, in more than one case a triple antibiotic mix taken orally over the course of several months has significantly alleviated symptoms.

I am also interested in the actions of copper as a natural antibacterial in the body and especially so since copper is seen to be deficient by most people on a western diet. see other link here:- http://en.wikiped...n_health

Interesting re the issue of the fetus in above link and just why this seems to be an important evolutionary step and especially so since there are almost 200 enzymes in the body that compete just for copper...

Thanks